Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. The company expects net sales to be JPY 270,000 million, Operating profit to be JPY 38,500 million, profit attributable to owners of parent to be JPY 29,000 million or JPY 127.12 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,036 JPY | +2.50% | +4.03% | +6.79% |
Apr. 04 | Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen | MT |
Apr. 04 | Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.79% | 4.4B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4527 Stock
- News Rohto Pharmaceutical Co.,Ltd.
- Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024